Postmarketing surveillance - Lack of vigilance, lack of trust

被引：129

作者：

Fontanarosa, PB ^{[1
]}

Rennie, D ^{[1
]}

DeAngelis, CD ^{[1
]}

机构：

[1] JAMA, Chicago, IL 60610 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2004年 / 292卷 / 21期

关键词：

D O I：

10.1001/jama.292.21.2647

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：2647 / 2650

页数：4

共 31 条

[1]

Adverse drug event monitoring at the Food and Drug Administration - Your report can make a difference [J].

Ahmad, SR .

JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 (01) :57-60

[2]

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[3]

Postmarketing surveillance and adverse drug reactions - Current perspectives and future needs [J].

Brewer, T ;

Colditz, GA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (09) :824-829

[4]

The need for a national infrastructure to improve the rational use of therapeutics [J].

Califf, RM .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (04) :319-327

[5]

CARPENTER D, 2003, HLTH AFF MILLWOOD S

[6]

The political economy of FDA drug review: Processing, politics, and lessons for policy [J].

Carpenter, DP .

HEALTH AFFAIRS, 2004, 23 (01) :52-63

[7]

CAUCHON D, 2000, US TODAY 0925, pA1

[8]

Lessons from the withdrawal of rofecoxib - Patients would be safer if drug companies disclosed adverse events before licensing [J].

Dieppe, PA ;

Ebrahim, S ;

Martin, RM ;

Juni, P .

BRITISH MEDICAL JOURNAL, 2004, 329 (7471) :867-+

[9]

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs [J].

Graham, DJ ;

Staffa, JA ;

Shatin, D ;

Andrade, SE ;

Schech, SD ;

La Grenade, L ;

Gurwitz, JH ;

Chan, KA ;

Goodman, MJ ;

Platt, R .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21) :2585-2590

[10]

Postmarketing surveillance for drug safety: Surely we can do better [J].

Griffin, MR ;

Stein, CM ;

Ray, WA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) :491-494

← 1 2 3 4 →